



PATENT

PC6947A/6970AGCB

RECEIVED
90 MAY -8 AM 10:42
GROUP 180

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

STEPHEN P. GIBSON ET AL.

: EXAMINER:

E. PESELEV

SERIAL NO.: 07/142,888

:

FILED: JANUARY 11, 1988

: ART UNIT: 183

FOR: ANTIPARASITIC AGENTS AND
PROCESS FOR THEIR PREPARATION :
-----Hon. Commissioner of Patents and Trademarks
Washington, D.C. 20231SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.99

I hereby certify that this
correspondence is being
deposited with the United States
Postal Service as First Class mail
in an envelope addressed to:
Commissioner of Patents and
Trademarks, Washington, D.C.
20231, on this 24th day of
April, 19 90
By Roberto Lombardini

Sir:

Applicants herein make available to the Patent and
Trademark Office a copy of PTO-FB-A820 (4 pages) which
lists references cited by the Applicants. Copies of
the cited references are enclosed.

U.S. 4,378,353 discloses, inter alia, certain
C-076 derivatives and procedures for their isolation
from the fermentation broth of a C-076 producing strain
of Streptomyces avermitilis.

U.S. 4,328,335 discloses, inter alia, processes
for the conversion of certain C-076 compounds having a
sec-butyl or isopropyl group at the C-25 position to
certain other C-076 compounds having a sec-butyl or
isopropyl group at the C-25 position.

U.S. 4,285,963 discloses, inter alia, certain C-076 compounds and their isolation from the fermentation broth of a C-076 producing strain of Streptomyces avermitilis.

U.S. 4,199,569 discloses, inter alia, certain C-076 compounds which contain an isopropyl or sec-butyl group at the C-25 position and certain processes to produce those compounds.

U.S. 4,200,581 discloses, inter alia, certain C-076 compounds which contain an isopropyl or sec-butyl group at the C-25 position and certain processes to produce those compounds.

U.S. 4,831,016 discloses, inter alia, derivatives of avermectin compounds wherein the 8,9 double bond and/or the 10,11 double bond is reduced and which contain a methyl, ethyl, isopropyl, sec-butyl or $C(CH_3)=CHR_{10}$ group, where R_{10} is methyl, ethyl or isopropyl, at the C-25 position.

U.S. 4,310,519 discloses, inter alia, certain C-076 compounds which contain an isopropyl or sec-butyl group at the C-25 position and a process for producing those compounds with a strain of Streptomyces avermitilis.

U.S. 4,429,042 discloses, inter alia, certain C-076 compounds which contain an isopropyl or sec-butyl group at the C-25 position and a process for producing those compounds with a strain of Streptomyces avermitilis.

EP 241 147 discloses, inter alia, a process for the production of antibiotic S541 by microorganisms belonging to the genus Streptomyces. That reference is cited herein to bring to the Examiner's attention the possibility that a U.S. counterpart application could be pending.

EP 215 654 discloses, inter alia, certain derivatives of antibiotic S541. That reference is cited herein to bring to the Examiner's attention the possibility that a U.S. counterpart application could be pending.

Schulman, et al., Fed. Proc. 44:931 (1985) discloses, inter alia, that certain mutants of Streptomyces avermitilis have been isolated which are deficient in the enzyme avermectin B O-methyltransferase and produce primarily avermectin B.

Chen, et al. disclose, inter alia, that C-25 moieties and the sec-butyl side chain of the a component and the isopropyl side chain of the b component of avermectins produced by Streptomyces avermitilis are derived directly from 2-methyl butyrate and isobutyrate, respectively.

Fisher & Mrozik disclose, inter alia, certain avermectin and milbemycin compounds and certain interconversions thereof.

Schulman, et al., J. Antibiot. 38(11):1494-1498 (1985) discloses, inter alia, the effect of sinefungin

on avermectin production by certain strains of Streptomyces avermitilis and the isolation, identification and biological activity of certain demethylavermectins produced in the presence of sinefungin.

Ruby, et al. disclose, inter alia, certain mutants of Streptomyces avermitilis which produced either predominately certain B avermectins or certain desmethyl avermectin A and B compounds.

Schulman, et al., Antimicrobial Agents and Chemotherapy 29:620-624 (1986) disclose, inter alia, certain Streptomyces avermitilis mutants with increased ability to produce certain avermectins.

Schulman, et al., Antimicrobial Agents and Chemotherapy 31:744-747 (1987) disclose, inter alia, certain Streptomyces avermitilis mutants defective in the methylation of avermectins and certain avermectins produced by those mutants.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 CFR 1.104(a). It is believed the Examiner will concur with Applicants' belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on Form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Dated: April 24, 1990



Gregg L. Benson
Attorney for Applicants
Reg. No. 30,997
(203) 441-4901

Enclosures

Pfizer Inc.
Legal-Patents
Eastern Point Road
Groton, CT 06340